FDA Briefs - March 1, 2002


Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
© 2023 MJH Life Sciences

All rights reserved.